Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis

Abstract

Càncer de mama; Marcadors predictius; Pronòstic

Cáncer de mama; Marcadores predictivos; Pronóstico

Breast cancer; Predictive markers; Prognosis

Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced/MBC from studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-receptor status. Eribulin appeared efficacious in patients with locally advanced/MBC, irrespective of the location of metastases at baseline. A nominally significant difference in OS in favor of patients randomized to eribulin compared with control in patients with bone, lymph node, and chest wall/breast/skin metastases at baseline was observed. Additionally, a difference in OS was also seen in patients with liver metastases randomized to eribulin versus control (median: 13.4 versus 11.3 months, respectively; hazard ratio, 0.84 [95% CI: 0.72, 0.97]). Results of this exploratory analysis suggest that eribulin may be efficacious for the treatment of locally advanced/MBC for patients with bone, liver, lung, lymph node, and chest wall/breast/skin metastases.

This study was funded by Eisai Inc., Woodcliff Lake, NJ. Medical writing support was provided by Jeffrey Bratz, PhD, Oxford PharmaGenesis, Newtown, PA, USA, and was funded by Eisai Inc., Woodcliff Lake, NJ, USA.